HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC.
Eligibility criteria
Qualifiers
primary infiltrative HCC according to MRI or CT imaging characteristics.
Child-Pugh class A or B, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
Lenvatinib as initial treatment.
patients received HAIC and PD-1 inhibitor in HAIC+Len+PD-1 group, patients received Lenvatinib alone in Len group.
Disqualifiers
HCC with tumor capsule.
under 18 years or over 75 years.
TACE as initial treatment.
sorafenib or other systemic therapy with or without PD-1 inhibitor following HAIC.
Trial design
Treatments tested in this trial
- Hepatic arterial infusion chemotherapy
- Lenvatinib
- Tislelizumab
- Toripalimab
- Sintilimab
- Camrelizumab
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov